Klonopin is the brand name for clonazepam, a benzodiazepine prescribed for seizure disorders and panic attacks. Whether it shows up on a drug test depends on which test is used, what the assay is calibrated to detect, and whether the specimen goes on to lab confirmation. The short answer employers and clinics need to know: many standard benzodiazepine immunoassay screens have historically shown reduced sensitivity to clonazepam and its main metabolite, which means a screening test can come back negative even when clonazepam is present. Confirmation testing closes that gap.
What clonazepam is and how the body processes it
Clonazepam is a long acting benzodiazepine. According to the National Institutes of Health StatPearls reference, clonazepam is extensively metabolized by the liver, with an elimination half life of roughly 30 to 40 hours, and its major metabolite, 7 aminoclonazepam, is excreted mainly in the urine. That long half life is exactly why detection windows for clonazepam tend to run longer than shorter acting benzodiazepines, but a long detection window only matters if the test being used is actually built to catch the drug.
Why some benzodiazepine screens miss clonazepam
Urine drug screening for benzodiazepines is usually done first with an immunoassay, a fast chemical test that reacts to a target molecule and any structurally similar compounds. The problem is that not every benzodiazepine cross reacts with a given immunoassay at the same strength. A 2024 study published through the National Institutes of Health's PubMed Central compared two commercial benzodiazepine immunoassays against liquid chromatography tandem mass spectrometry (LC-MS/MS) and found that clonazepam and lorazepam metabolites have historically shown low sensitivity in benzodiazepine immunoassays. Even an improved assay in that study, selected specifically because it cross reacts better with clonazepam and lorazepam metabolites, still failed to detect 27 percent of specimens that were positive by LC-MS/MS confirmation. In practice, this means a benzodiazepine immunoassay calibrated primarily around a different reference compound can under detect clonazepam and 7 aminoclonazepam at concentrations that would otherwise be reported positive by a more specific method.
This is not a reason to distrust drug testing generally. It is a reason to understand what a screening result does and does not prove, and why confirmation testing exists.
Cross reactivity works because immunoassays are built around antibodies trained to bind a specific target molecule, and the manufacturer picks that target based on which benzodiazepine metabolite is most common or easiest to standardize against across a population. Different manufacturers make different choices, so two BZO immunoassays from two different vendors can perform very differently against the same clonazepam positive specimen. A laboratory that only reports the initial immunoassay result, without confirmation, is passing along a result that reflects the quirks of that particular assay rather than a definitive answer about what was actually in the specimen. This is one of the reasons drug testing programs that care about accuracy build confirmation into their standard workflow rather than treating it as an exception.
| Factor | What it means for testing |
|---|---|
| Drug class | Benzodiazepine, DEA Schedule IV controlled substance |
| Primary metabolite | 7 aminoclonazepam, excreted in urine |
| Elimination half life | Approximately 30 to 40 hours (varies by individual) |
| Initial screen | Benzodiazepine (BZO) immunoassay, cross reactivity varies by manufacturer and target compound |
| Confirmation method | GC-MS or LC-MS/MS, identifies clonazepam and 7 aminoclonazepam specifically |
| Federal five panel (DOT) | Benzodiazepines are not part of the federally mandated five panel test; many non-DOT employer panels add a BZO screen separately |
| Prescription documentation | Reviewed by the Medical Review Officer before a result is reported to an employer |
Screening versus confirmation: why the distinction matters here
An immunoassay screen is a presumptive test. A non-negative screen should always go to confirmation by gas chromatography mass spectrometry (GC-MS) or LC-MS/MS, which separates and identifies specific compounds rather than reacting to a class of similar molecules. For clonazepam, confirmation testing can specifically identify 7 aminoclonazepam, removing the guesswork that comes with cross reactivity. This is also why a negative benzodiazepine screen should not be read as definitive proof that no benzodiazepine was used. It only means the immunoassay did not detect a concentration above its cutoff for the compound it is calibrated against. Laboratories and medical review officers who understand this build their programs around confirmation rather than relying on the screen alone.
Does DOT drug testing include Klonopin?
No. Benzodiazepines, including clonazepam, are not part of the federally mandated drug testing panel that the Department of Transportation requires for safety sensitive transportation employees. That panel is limited to marijuana metabolites, cocaine metabolites, amphetamines, opioids, and phencyclidine. Employers who want benzodiazepine screening for DOT covered employees, or for any workforce, generally have to add a separate non-DOT panel or a specific BZO addition through their testing provider. This is a program design decision, and one that should be documented clearly in a written drug testing policy so employees understand exactly what is and is not being tested.
This gap surprises a lot of employers who assume any drug test covers any drug. In reality, every testing panel is a defined list, and benzodiazepines have simply never been part of the mandatory federal panel that governs safety sensitive transportation testing. Employers in industries outside DOT jurisdiction, including healthcare, manufacturing, and general workforce screening, have more flexibility to design a panel that includes benzodiazepines, but that flexibility comes with the responsibility to understand what the chosen panel actually detects and how reliably it detects it.
Prescription documentation and the Medical Review Officer
Clonazepam is a Schedule IV controlled substance under the DEA's Controlled Substances Act schedule, meaning it is legal to possess and use only with a valid prescription. When a benzodiazepine screen returns non-negative and confirmation identifies clonazepam or 7 aminoclonazepam, a Medical Review Officer (MRO) reviews the result before it is reported to the employer. The MRO's job is to determine whether there is a legitimate medical explanation, generally a current prescription, and to verify that documentation directly with the individual and, if needed, the prescribing provider. Employers should never attempt to interpret a lab result on their own or make employment decisions before the MRO review is complete. This process protects both the accuracy of the program and the rights of employees who are taking a lawfully prescribed medication.
What this means for testing programs
For employers, clinics, and testing programs building or reviewing a drug testing panel, a few practical points follow from the science:
- If detecting clonazepam use is a program priority, confirm with your laboratory which benzodiazepine immunoassay they use and what its documented cross reactivity is for clonazepam and 7 aminoclonazepam, since sensitivity varies by manufacturer and by which reference compound the assay is calibrated against.
- A negative benzodiazepine screen is not the same as a confirmed negative for clonazepam specifically. Programs that need higher confidence should route non-negative or borderline results to LC-MS/MS or GC-MS confirmation rather than relying on the immunoassay alone.
- Benzodiazepines are not included in DOT's mandated five panel test. Programs that want this coverage need to add it explicitly.
- Any confirmed positive result should go through MRO review before any employment action, with the individual given the opportunity to provide valid prescription documentation.
Frequently asked questions
Does Klonopin always show up on a standard drug test?
Not necessarily. Standard benzodiazepine immunoassay screens vary in how well they detect clonazepam and its metabolite, 7 aminoclonazepam, because cross reactivity depends on the specific assay and reference compound used. A test can return negative even when clonazepam is present in a low or moderate concentration.
How long does clonazepam stay detectable in urine?
Clonazepam has a long elimination half life, generally cited around 30 to 40 hours, and detection windows vary by individual metabolism, dose, and frequency of use. Because this varies significantly, no fixed number of days applies to everyone, and specific timing questions are best directed to a laboratory toxicologist or medical provider.
Is clonazepam part of the federal five panel drug test?
No. The federally mandated panel used for DOT safety sensitive testing covers marijuana metabolites, cocaine metabolites, amphetamines, opioids, and phencyclidine. Benzodiazepines are not included and must be added separately if a program wants that coverage.
What happens if a benzodiazepine screen is positive but the person has a prescription?
A Medical Review Officer reviews the confirmed result and any prescription documentation before the result is reported to the employer. A valid, current prescription for a legitimately prescribed medication is the kind of information the MRO process exists to verify.
Why do some labs use LC-MS/MS instead of just the initial screen for benzodiazepines?
Immunoassay screens are fast and inexpensive but can under detect certain benzodiazepines, including clonazepam, depending on the assay's cross reactivity profile. LC-MS/MS and GC-MS confirmation methods identify specific compounds and metabolites, which is why non-negative screens are routed to confirmation rather than reported as final results on their own.
Is Klonopin a controlled substance?
Yes. Clonazepam is listed as a Schedule IV controlled substance under the federal Controlled Substances Act, meaning it has an accepted medical use but also a recognized potential for misuse and dependence relative to non scheduled medications.
Related reading
- Benzodiazepine Drug Test: BZO Panel Detection Times and Gaps
- The Medical Review Officer (MRO) Process Explained for Employers
Employers and clinics building or reviewing a benzodiazepine testing program can find reliable panels, including expanded options, in American Screening Corporation's drug test cups collection.
Sources
- Clonazepam, StatPearls, NCBI Bookshelf (National Institutes of Health)
- Benzodiazepine immunoassay performance study, PubMed Central (National Institutes of Health)
- Clonazepam, MedlinePlus Drug Information (National Institutes of Health)
- Controlled Substances, Alphabetical Order, DEA Diversion Control Division (U.S. Department of Justice)
This article is general information only and is not legal or medical advice. Drug testing policies, panel selection, and prescription review should be handled with qualified legal counsel and a Medical Review Officer.
